The chart does not show that the treatment is beneficial to 35% of patients. It shows that it's beneficial to 3.2% of patients: Where 11.9% of patients died without it, only 8.7% died with it. 8.7% is ~35% lower than 11.9%, but the difference is not 35% of patients.

— James HG Redekop 🌻🏳️‍🌈 (@JHGRedekop) August 24, 2020